Cascade Chemistry to produce API for COVID-19 trial

By Jenni Spinner contact

- Last updated on GMT

(Irina Shibanova/iStock via Getty Images Plus)
(Irina Shibanova/iStock via Getty Images Plus)

Related tags: API, Manufacturing, Clinical trial, COVID-19, Coronavirus

Tapped by Renibus Therapeutics, the CDMO will produce the API for clinical trials of investigational drug RBT-9 for an upcoming COVID-19 study.

Cascade Chemistry, a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, will produce the active pharmaceutical ingredient (API) for RBT-9 on behalf of client Renibus Therapeutics. The investigational therapy is entering a Phase II trial for COVID-19 patients at high risk due to age or comorbid conditions (such as kidney or cardiovascular disease).

RBT-9 is being developed by Renibus Therapeutics as an antiviral treatment with organ-protective attributes. The drug, recently awarded fast track designation by the US Food and Drug Administration (FDA) reportedly has demonstrated antiviral properties as well as immune-modulating activities in preclinical studies.

At the onset of the COVID-19 pandemic, Renibus Therapeutics reportedly worked quickly to plan and initiate an RVT-9 trial for COVID-19 patients. According to Cascade Chemistry, Renibus chose its production partner based on experience, flexibility and service focus.

Alvaro Guillem, CEO of Renibus Therapeutics, said Cascade Chemistry offered the knowledge and capabilities necessary to orchestrate and implement an effective strategy.

Cascade’s ability to move quickly to design, implement, and scale-up a comprehensive RBT-9 API manufacturing strategy has been one of the essential elements in our campaign to initiate clinical trials with minimal delay​,” Guillem said. “The professionalism, expertise, flexibility, and client commitment of the Cascade team have facilitated our collaborative effort to advance effective therapies for this devastating global pandemic​."

Jeremiah Marsden, Cascade Chemistry president, added that his company was eager for the opportunity to partner with Renibus to produce the necessary API to accelerate RBT-9 into clinical trials for the virus.

Our reputation as a reliable, experienced, and flexible outsourcing partner with exceptional chemistry problem-solving expertise is based on our many past successes with Renibus and other clients. These qualities are serving us well as we work to complete this important project with impeccable quality and all possible speed​,” Marsden said.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more